46.24
price up icon2.19%   0.99
after-market アフターアワーズ: 46.24
loading
前日終値:
$45.25
開ける:
$44.77
24時間の取引高:
1.22M
Relative Volume:
1.52
時価総額:
$3.57B
収益:
$900.66M
当期純損益:
$-453.20M
株価収益率:
-5.3457
EPS:
-8.65
ネットキャッシュフロー:
$-274.19M
1週間 パフォーマンス:
-0.28%
1か月 パフォーマンス:
+10.20%
6か月 パフォーマンス:
+38.90%
1年 パフォーマンス:
+71.01%
1日の値動き範囲:
Value
$44.74
$47.42
1週間の範囲:
Value
$44.30
$48.77
52週間の値動き範囲:
Value
$23.58
$54.16

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Name
名前
Ptc Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
(908) 222-7000
Name
住所
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Name
職員
995
Name
Twitter
@PTCBio
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
PTCT's Discussions on Twitter

PTCT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PTCT
Ptc Therapeutics Inc
46.24 3.57B 900.66M -453.20M -274.19M -5.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-13 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-03 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-10-10 再開されました Raymond James Mkt Perform
2024-09-04 開始されました Robert W. Baird Outperform
2024-08-26 再開されました UBS Buy
2024-05-20 アップグレード Raymond James Underperform → Mkt Perform
2023-12-19 ダウングレード Morgan Stanley Equal-Weight → Underweight
2023-12-08 開始されました Wells Fargo Overweight
2023-10-30 アップグレード Oppenheimer Perform → Outperform
2023-10-27 ダウングレード Citigroup Neutral → Sell
2023-10-06 ダウングレード Truist Buy → Hold
2023-09-18 ダウングレード Citigroup Buy → Neutral
2023-09-15 ダウングレード Raymond James Outperform → Underperform
2023-03-17 開始されました SVB Securities Market Perform
2022-12-14 開始されました Goldman Sell
2022-09-12 開始されました Jefferies Buy
2022-09-09 開始されました Morgan Stanley Equal-Weight
2022-09-01 開始されました Citigroup Buy
2022-04-04 再開されました Cantor Fitzgerald Overweight
2021-10-18 ダウングレード BofA Securities Neutral → Underperform
2021-04-26 再開されました Credit Suisse Neutral
2021-03-29 アップグレード RBC Capital Mkts Underperform → Sector Perform
2021-02-12 ダウングレード BofA Securities Buy → Neutral
2021-01-05 アップグレード Citigroup Neutral → Buy
2020-11-30 ダウングレード RBC Capital Mkts Sector Perform → Underperform
2020-10-30 ダウングレード Citigroup Buy → Neutral
2020-10-28 開始されました UBS Neutral
2020-10-07 アップグレード JP Morgan Neutral → Overweight
2020-08-25 開始されました Raymond James Outperform
2020-04-09 アップグレード Citigroup Neutral → Buy
2020-02-20 ダウングレード Citigroup Buy → Neutral
2020-02-20 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-11-12 開始されました SunTrust Buy
2019-05-13 アップグレード BofA/Merrill Neutral → Buy
2019-04-11 開始されました Bernstein Outperform
2018-10-03 アップグレード BofA/Merrill Underperform → Neutral
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-07-19 開始されました Credit Suisse Outperform
2018-06-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-04-04 ダウングレード Barclays Equal Weight → Underweight
2018-01-29 再開されました RBC Capital Mkts Sector Perform
2017-11-16 アップグレード JP Morgan Underweight → Neutral
2017-10-26 ダウングレード BofA/Merrill Neutral → Underperform
2017-10-09 ダウングレード JP Morgan Neutral → Underweight
すべてを表示

Ptc Therapeutics Inc (PTCT) 最新ニュース

pulisher
Dec 21, 2024

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN

Dec 21, 2024
pulisher
Dec 20, 2024

PTC upgraded to outperform by RBC on Novartis deal - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

PTC Therapeutics ALS drug fails to meet endpoints as trials shut down - MSN

Dec 20, 2024
pulisher
Dec 19, 2024

PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone - MSN

Dec 19, 2024
pulisher
Dec 19, 2024

PTC Therapeutics Submits Vantiquinone NDA To FDA - Contract Pharma

Dec 19, 2024
pulisher
Dec 19, 2024

PTC Therapeutics submits FDA application for FA treatment - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

PTC Therapeutics Seeks FDA Approval for Groundbreaking Friedreich Ataxia Treatment in Children - StockTitan

Dec 19, 2024
pulisher
Dec 19, 2024

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald

Dec 19, 2024
pulisher
Dec 19, 2024

PTC Therapeutics Submits Vantiquinone NDA to FDA - Contract Pharma

Dec 19, 2024
pulisher
Dec 18, 2024

PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to "Hold" at StockNews.com - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

PTC Therapeutics, Inc. Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia - Marketscreener.com

Dec 18, 2024
pulisher
Dec 18, 2024

PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows - MSN

Dec 18, 2024
pulisher
Dec 17, 2024

PTC Therapeutics Grants New Employee Stock Options and RSUs in Strategic Talent Acquisition Move - StockTitan

Dec 17, 2024
pulisher
Dec 16, 2024

PTC Therapeutics' SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Y Intercept Hong Kong Ltd Sells 18,312 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

State Street Corp Purchases 149,700 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 16, 2024
pulisher
Dec 14, 2024

Morgan Stanley Upgrades PTC Therapeutics (PTCT) - MSN

Dec 14, 2024
pulisher
Dec 13, 2024

Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha

Dec 13, 2024
pulisher
Dec 13, 2024

PTC Therapeutics upgraded to Overweight at Morgan Stanley - MSN

Dec 13, 2024
pulisher
Dec 13, 2024

PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Overweight at Morgan Stanley - MarketBeat

Dec 13, 2024
pulisher
Dec 12, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat

Dec 12, 2024
pulisher
Dec 09, 2024

Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast - BioCentury

Dec 09, 2024
pulisher
Dec 09, 2024

Two Sigma Advisers LP Grows Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Fmr LLC Trims Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 09, 2024
pulisher
Dec 08, 2024

Wellington Management Group LLP Sells 315,807 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 08, 2024
pulisher
Dec 07, 2024

BNP Paribas Financial Markets Sells 54,655 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 07, 2024
pulisher
Dec 06, 2024

At $1B, PTC-Novartis deal ties record for cash up front - BioCentury

Dec 06, 2024
pulisher
Dec 06, 2024

Janus Henderson Group PLC Sells 1,111,342 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Global Leigh Syndrome Treatment Market Outlook: Key Trends, - openPR

Dec 06, 2024
pulisher
Dec 05, 2024

PTC Therapeutics (STU:BH3) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024
pulisher
Dec 05, 2024

PTC Therapeutics (STU:BH3) 9-Day RSI : 64.15 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024
pulisher
Dec 05, 2024

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy - MSN

Dec 05, 2024
pulisher
Dec 05, 2024

Ptc Therapeutics exec VP sells shares worth $5 million By Investing.com - Investing.com Canada

Dec 05, 2024
pulisher
Dec 05, 2024

PTC Therapeutics director Jerome Zeldis sells $1.24m in stock By Investing.com - Investing.com Canada

Dec 05, 2024
pulisher
Dec 05, 2024

Charles Schwab Investment Management Inc. Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 05, 2024
pulisher
Dec 04, 2024

PTC Therapeutics price target raised to $41 from $31 at BofA - MSN

Dec 04, 2024
pulisher
Dec 04, 2024

Ptc Therapeutics' chief accounting officer sells shares worth $921,585 By Investing.com - Investing.com Canada

Dec 04, 2024
pulisher
Dec 04, 2024

Insider Sell Alert: Christine Utter Sells 17,800 Shares of PTC T - GuruFocus.com

Dec 04, 2024
pulisher
Dec 04, 2024

Insider Sell Alert: Jerome Zeldis Sells 24,000 Shares of PTC The - GuruFocus.com

Dec 04, 2024
pulisher
Dec 04, 2024

Ptc Therapeutics exec VP sells shares worth $5 million - Investing.com

Dec 04, 2024
pulisher
Dec 04, 2024

Ptc Therapeutics' chief accounting officer sells shares worth $921,585 - Investing.com

Dec 04, 2024
pulisher
Dec 04, 2024

PTC Therapeutics director Jerome Zeldis sells $1.24m in stock - Investing.com

Dec 04, 2024
pulisher
Dec 04, 2024

PTC Therapeutics' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com Nigeria

Dec 04, 2024
pulisher
Dec 04, 2024

PTC Therapeutics price target raised to $70 from $52 at Baird - MSN

Dec 04, 2024
pulisher
Dec 04, 2024

Parkman Healthcare Partners LLC Takes $7.23 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 04, 2024
pulisher
Dec 04, 2024

PTC Therapeutics price target raised to $71 from $47 at UBS - Yahoo Finance

Dec 04, 2024
pulisher
Dec 04, 2024

Jacobs Levy Equity Management Inc. Sells 229,494 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Dec 04, 2024
pulisher
Dec 04, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Dec 04, 2024
pulisher
Dec 04, 2024

Ptc Therapeutics' chief technical officer sells shares worth $3.6 million - Investing.com

Dec 04, 2024
pulisher
Dec 04, 2024

PTC Therapeutics' SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa

Dec 04, 2024
pulisher
Dec 03, 2024

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone - MSN

Dec 03, 2024

Ptc Therapeutics Inc (PTCT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ptc Therapeutics Inc (PTCT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Almstead Neil Gregory
CHIEF TECHNICAL OPS OFFICER
Dec 02 '24
Option Exercise
51.00
2,060
105,060
6,636
Almstead Neil Gregory
CHIEF TECHNICAL OPS OFFICER
Dec 02 '24
Sale
52.06
69,550
3,620,895
86,202
Almstead Neil Gregory
CHIEF TECHNICAL OPS OFFICER
Dec 02 '24
Sale
51.97
2,060
107,063
4,576
ZELDIS JEROME B
Director
Dec 02 '24
Option Exercise
40.93
24,000
982,320
26,500
ZELDIS JEROME B
Director
Dec 02 '24
Sale
51.50
24,000
1,235,897
14,500
Utter Christine Marie
SVP, CHIEF ACCOUNTING OFFICER
Dec 02 '24
Option Exercise
51.00
17,800
907,800
67,123
Utter Christine Marie
SVP, CHIEF ACCOUNTING OFFICER
Dec 02 '24
Sale
51.77
17,800
921,585
52,428
Boulding Mark Elliott
EXEC. VP AND CLO
Dec 02 '24
Option Exercise
51.00
85,600
4,365,600
176,029
Boulding Mark Elliott
EXEC. VP AND CLO
Dec 03 '24
Option Exercise
33.02
10,308
340,370
100,109
Boulding Mark Elliott
EXEC. VP AND CLO
Dec 02 '24
Sale
52.26
85,600
4,473,280
92,389
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):